Abstract
We describe a case of a 4-year-old girl with Burkitt's lymphoma, who suffered from a massive gastrointestinal hemorrhage 3 days after chemotherapy. In spite of applying the common practice in correction of coagulopathy, thrombocytopenia persisted and bleeding became life-threatening. In the present case report, we report a successful control of bleeding with a single-dose administration of a biosimilar recombinant activated human factor VII (AryoSeven).
Highlights
Recombinant activated human factor VII is a hemostatic agent principally licensed to treat bleeding episodes and perioperative management in hemophilia A or B adults and children with inhibitors and adults with acquired hemophilia, congenital factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia
It is assumed that the use of rFVIIa can be beneficial in providing hemostasis in other situations characterized by massive bleedings and impaired thrombin generation [2]
AryoSeven is an rFVIIa recently manufactured via recombinant technology in Iran by AryoGen pharmed
Summary
Recombinant activated human factor VII (rFVIIa) is a hemostatic agent principally licensed to treat bleeding episodes and perioperative management in hemophilia A or B adults and children with inhibitors and adults with acquired hemophilia, congenital factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia. These indications may be presented only in a small population. It is assumed that the use of rFVIIa can be beneficial in providing hemostasis in other situations characterized by massive bleedings and impaired thrombin generation [2]. We report a Burkitt’s lymphoma case suffering from a massive GI bleeding which was controlled with a single administration of AryoSeven following the unresponsive transfusion of appropriate blood products
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
